Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Multiple Myeloma 202Leukemia, Lymphocytic, Chronic, B-Cell 54Recurrence 37Neoplasms, Plasma Cell 30Lymphoma, Mantle-Cell 30Lymphoma 30Lymphoma, Follicular 29Lymphoma, Large B-Cell, Diffuse 27Leukemia 23Leukemia, Myeloid, Acute 22Lymphoma, Non-Hodgkin 21Lymphoma, B-Cell, Marginal Zone 15Myelodysplastic Syndromes 13Hodgkin Disease 12Waldenstrom Macroglobulinemia 8Prostatic Neoplasms 8Lymphoma, T-Cell 8Smoldering Multiple Myeloma 7Immunoglobulin Light-chain Amyloidosis 7Neoplasms 6Melanoma 6Lymphoma, B-Cell 6Hematologic Diseases 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myelomonocytic, Chronic 5Hematologic Neoplasms 5Amyloidosis 5Sezary Syndrome 4

Interventions

Iodine-131 5Sunitinib 3Magnetic Resonance Spectroscopy 3Trastuzumab 2Thyrotropin Alfa 2Gefitinib 2Fluorodeoxyglucose F18 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1trametinib 1tipifarnib 1tanespimycin 1sargramostim 1romidepsin 1pembrolizumab 1pazopanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lenvatinib 1dabrafenib 1cediranib 1aldesleukin 1aflibercept 1X-Rays 1Vorinostat 1Triiodothyronine 1Thalidomide 1Tamoxifen 1Surgical Procedures, Operative 1Semaxinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma, Follicular × Lenalidomide × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡